ESMO - Eur. Oncology· @myESMO · X·· 1 天前评分70
正文 · 原文
#ESMO26: Practice-changing results with savolitinib plus osimertinib after progression on osimertinib in selected patients with EGFR-mutated, MET-positive non-small cell #LungCancer (#NSCLC) in the SAFFRON trial.
Check out
🔗 https://ow.ly/iIJP50ZZGCp
#InsightsbyESMO
213 浏览 · 2 赞 · 0 转发 · 0 回复
来源：ESMO - Eur. Oncology · x.com